Top Markets
#1 Tornado Cash Tornado Cash +5.42%
#2 MVL MVL +3.98%
#3 Nockchain Nockchain +3.41%
#4 Story Story +3.25%
#5 Dual Dual +2.86%
#6 TENDIES TENDIES +2.76%
#7 UnifAI Network UnifAI Network +2.62%
#8 Figure Heloc Figure Heloc +2.55%
#9 WAX WAX +2.47%
#10 Seeker Seeker +2.13%
Coin of the day
Tornado Cash Tornado Cash
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AP Biosciences Inc AP Biosciences Inc

AP Biosciences Inc

6945
Classifica tra le azioni #16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Prezzo delle azioni
$3.06
Capitalizzazione di mercato
$296.40M
Variazione (1 giorno)
-2.24%
Variazione (1 anno)
-22.64%
Paese
TW
Scambia AP Biosciences Inc (6945)

Categoria

Healthcare
Utile per AP Biosciences Inc (6945)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di AP Biosciences Inc, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di AP Biosciences Inc dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH